Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1336403 | 0.84 | CACNA1B (0.49) | ACACBGRIN2BHCRTR1HCRTR2HRH3 | |
| SCHEMBL1335911 | 0.83 | CACNA1B (0.58) | ACACBGRIN2BHCRTR1HCRTR2CACNA1B | |
| SCHEMBL1337071 | 0.83 | GRIN2B (0.47) | ACACBGRIN2BHCRTR1HCRTR2HRH3 | |
| SCHEMBL1336617 | 0.82 | ACACB (0.46) | ACACBGRIN2BHCRTR1HCRTR2HRH3 | |
| SCHEMBL1336979 | 0.82 | CACNA1B (0.46) | ACACBGRIN2BCACNA1B | |
| SCHEMBL1335921 | 0.80 | GRIN2B (0.45) | ACACBGRIN2BHCRTR1HCRTR2HRH3 | |
| SCHEMBL66587 | 0.79 | CACNA1B (0.59) | ACACBGRIN2BCACNA1B | |
| SCHEMBL1336429 | 0.79 | CACNA1B (0.47) | ACACBGRIN2BHCRTR1HCRTR2HRH3 | |
| SCHEMBL1336615 | 0.79 | CACNA1B (0.51) | ACACBGRIN2BCACNA1B | |
| SCHEMBL1334989 | 0.78 | CACNA1B (0.53) | ACACBHCRTR1HCRTR2HRH3CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | claimed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | ACACB 2352/4885GRIN2B 219/4885HCRTR1 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.